VERB

 

Verb sell off 0.1994 100 share and 

buy back 0.20 for 100 share today 

avg price  0.7767centnet loss 74.25% 57.67 DOLLOR NET LOSS

current market 0.20cent 

 (company offering as of 01/24/2022  today market down 48.56%  (0.19cent down)

price up 0.58 on 01/20/2023

crash on 0.1902 on 01/24/2023

 

ST

ID	stock	number	price	Field1	plan	current price	share amount	current lost price	net loss	fill amount	filled price	fill total	grand total	grand share	grand avg	GAP
7	VERB	$100.00	$0.78	$77.67		$0.20	$100.00	$20.00	($57.67)	$0.00	$0.00	$0.00	$77.67	$100.00	$0.78

 

OGI PRICE HISTORY

 

PLUR

 

AKBA

 

OPEN

 

CRDL reverse buy back

NET LOSS 71.90 %  

AVG 2.72 (CURRENT VALUE 0.765) 

ST

ID	stock	number	price	Field1	plan	current price	share amount	current lost price	net loss	fill amount	filled price	fill total	grand total	grand share	grand avg	GAP
5	CRDL	$92.00	$2.72	$250.24		$0.67	$92.00	$61.64	($188.60)	$0.00	$0.00	$0.00	$250.24	$92.00	$2.72

  REPURCHASE 

ST

ID	stock	number	price	Field1	plan	current price	share amount	current lost price	net loss	fill amount	filled price	fill total	grand total	grand share	grand avg	GAP
6	CRDL	$101.00	$0.77	$77.27		$0.78	$101.00	$78.29	$1.02	$0.00	$0.00	$0.00	$77.27	$101.00	$0.77

 

ST

ID	stock	number	price	Field1	plan	current price	share amount	current lost price	net loss	fill amount	filled price	fill total	grand total	grand share	grand avg	GAP
6	CRDL	$101.00	$0.77	$77.27		$0.77	$100.00	$76.50	($0.77)	$0.00	$0.00	$0.00	$77.27	$101.00	$0.77

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is a clinical-stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for heart diseases.

Cardiol Therapeutics Inc (CRDL)

$1.37

+$0.08(+6.64%)Today

$1.47+$0.10(+7.30%)Pre-Market

Financial Overview:

• Revenue: For the fiscal year ending December 31, 2023, Cardiol Therapeutics reported minimal revenue, consistent with its status as a clinical-stage company.

  Yahoo Finance

• Net Loss: The company recorded a net loss of approximately $20.84 million for the same period, reflecting ongoing research and development expenditures.

  MarketBeat

• Cash Position: As of December 31, 2023, the company held cash and short-term investments totaling approximately $34.93 million, providing a financial runway for its clinical programs.

  The Wall Street Journal

Analyst Ratings and Price Targets:

• Consensus Rating: Cardiol Therapeutics has received a consensus rating of "Buy" from multiple analysts, indicating optimism about the company's prospects.

  MarketBeat

• Price Targets: The average twelve-month price target is $8.75, with estimates ranging from $7.89 to $10.00, suggesting a significant potential upside from the current share price.

  The Wall Street Journal

• Recent Analyst Activity: On December 18, 2024, HC Wainwright reiterated a "Buy" rating with a $9.00 price target, reflecting confidence in the company's strategic direction.

  MarketBeat

Recent Developments:

• Clinical Trials: 

  Stock Analysis

• The company has completed patient enrollment in its Phase II 

• MAvERIC-Pilot study investigating CardiolRx™ for recurrent pericarditis, with topline results expected in Q2 2024.

• Regulatory Designations: CardiolRx™ has been granted Orphan Drug Designation by the U.S. FDA for the treatment of pericarditis, potentially expediting its development and approval process.

  Stock Analysis

Considerations for Investors:

While Cardiol Therapeutics shows promise with its innovative therapies and favorable analyst outlook, potential investors should be mindful of the inherent risks associated with clinical-stage biotech companies, including regulatory hurdles, clinical trial outcomes, and market competition.

It's advisable to conduct thorough due diligence and consider these factors when evaluating investment opportunities in the biotech sector.

 

CALA REVERSE BUY BACK

TODAY SELL OFF CALA AND BUY BACK

NET LOSS 22 $ TO GET BACK CALA 

RIGHT NOW GAIN 1.29 

TO WAIT TILL 22 $ TRADE IN AND OUT

MULN reverse net loss 40$ buy 600 share

 NET LOSS 303 $ GAIN 80 $ TO GET 223

  NET LOSS 40 $ GAIN 0   $ TO GET 40 

TO GET TOTAL 263 $

 

MULN SELL OFF  4  JAN    2023 1100 SHARE 0.32  TOTAL 352 $ MULN SELL OFF     29 DEC  2022 1000 SHARE 0.26 TOTAL 260 $

  

ID	stock	number	price	TOTAL PRICE	plan	current price	NUMBER OF SHARE	current lost price	net loss	fill amount	filled price	fill total	grand total	grand share	grand avg	GAP
15	MULN	$520.00	$0.22	$115.28		$0.22	$520.00	$112.22	($3.07)	$520.00	$0.22	$112.27	$227.55	$1,040.00	$0.22
14	MULN	$520.00	$0.80	$416.00		$0.22	$520.00	$112.22	($303.78)	$0.00	$0.00	$0.00	$416.00	$520.00	$0.80
23	MULN	$4,000.00	$0.24	$960.00		$0.30	$4,000.00	$1,200.00	$240.00	$0.00	$0.00	$0.00	$960.00	$4,000.00	$0.24

 

MULN FILL THE SHORT

  MULN SELL OFF  4  JAN    2023 1100 SHARE 0.32  TOTAL 352 $ MULN SELL OFF     29 DEC  2022 1000 SHARE 0.26 TOTAL 260 $

  

ID	stock	number	price	TOTAL PRICE	plan	current price	NUMBER OF SHARE	current lost price	net loss	fill amount	filled price	fill total	grand total	grand share	grand avg	GAP
15	MULN	$520.00	$0.22	$115.28		$0.22	$520.00	$112.22	($3.07)	$520.00	$0.22	$112.27	$227.55	$1,040.00	$0.22
14	MULN	$520.00	$0.80	$416.00		$0.22	$520.00	$112.22	($303.78)	$0.00	$0.00	$0.00	$416.00	$520.00	$0.80
23	MULN	$4,000.00	$0.24	$960.00		$0.30	$4,000.00	$1,200.00	$240.00	$0.00	$0.00	$0.00	$960.00	$4,000.00	$0.24